BIONTECH SE SPON. ADRS 1
Commented by Fabian Lorenz on August 10th, 2022 | 10:18 CEST
BioNTech, BYD, Altech Advanced Materials: Excitement is rising
So much for the summer slump. The stock markets are generally friendly at the moment, and many shares are reacting with significant price swings to news, both negative and positive. Like with BioNTech, the share price fell sharply after an impressive rally after the quarterly figures. There are good reasons for rising prices in the coming weeks. BYD is also going full throttle operationally. The e-car manufacturer is reporting one sales record after another, and details are emerging about the launch in Germany to knock Tesla off its electric throne. E-cars, possibly also from BYD, are expected to incorporate battery technology from Altech Advanced Materials in the future. The Company is working on revolutionary technology, and new details are expected by the time of the AGM.
Read
Commented by Armin Schulz on August 9th, 2022 | 13:45 CEST
BioNTech, Defence Therapeutics, Valneva - Will biotech stocks continue to rally in the fall?
The NASDAQ Biotechnology Index formed a double bottom in mid-June and has since rallied, breaking the downtrend. However, there is still over 32% potential to the past highs. The highs are due in part to the sales from the Corona Crisis, but even though currently the issue is not as present despite higher case numbers, that could change in the fall. The new Protection Against Infection Act provides for mask-wearing and further vaccinations. The profits from these sales are often invested in the development of new therapies, such as cancer research. These areas hold a lot of potential for rising share prices. We take a closer look at three biotech companies.
Read
Commented by Juliane Zielonka on August 5th, 2022 | 11:54 CEST
Meta Materials, JinkoSolar, BioNTech - Smart technologies as growth boosters
Solar and photovoltaic companies have been hot in the financial markets since the shifts in the energy market. Chinese supplier JinkoSolar, for example, is now launching solar batteries for home use. Smart buildings are an important component in urban city planning. Where there is plenty of sunshine, its energy is converted for personal use, and Australian residents are benefiting from JinkoSolar's technology. In order to increase the efficiency of such energy sources, Meta Materials offers innovative solutions that make solar systems even more cost-effective. Thanks to numerous patents, they also have a business model, which will please long-term investors in terms of growth opportunities. Rather unpleasant, however, are the measures planned by the German government for the coming fall and winter. Masks or vaccination is the calculation, which will at least bring some joy to BioNTech shareholders.
Read
Commented by Fabian Lorenz on August 3rd, 2022 | 10:50 CEST
Varta at EUR 64 or EUR 102? Will BioNTech and Kleos Space make the breakout?
The stock market environment is currently friendly, and technology stocks, in particular, are in a recovery rally. Investors are driven by the hope that inflation will weaken and that an end to the interest rate increase cycle of the US Federal Reserve will at least become foreseeable. If this were the case, we would not be in a bear market rally, but at the beginning of a new bull market. But not all stocks have been able to benefit from the good mood in recent weeks. Rightly so? In the case of Varta, the answer is yes - the Company shocked shareholders with a profit warning on Saturday. However, the price targets of analysts diverge significantly. The BioNTech share is unusually quiet. There is positive news from the Company itself and its partner Pfizer. With the quarterly figures next week, an attempt to break out of the sideways trend could take place. Kleos Space is also currently making this attempt. Investors are positioning themselves with the high-tech company in preparation for the next milestone.
Read
Commented by Nico Popp on August 2nd, 2022 | 10:57 CEST
These sources of return concern us all: Fresenius, Defence Therapeutics, BioNTech
When people receive an unexpected diagnosis or a loved one suddenly dies, our health suddenly becomes very important. Even though there is often no room for such topics in the daily lives of investors, it is worthwhile to deal with health for several reasons. On the one hand, preventive care brings the most important of all returns; on the other hand, this rather unpleasant topic in everyday life also holds opportunities if we focus on health risks and look at possible solutions. We present three stocks from the healthcare sector that deserve attention.
Read
Commented by André Will-Laudien on July 28th, 2022 | 14:20 CEST
Finding the next BioNTech: MorphoSys, XPhyto Therapeutics, Formycon - Who will make the breakthrough?
The Mainz-based biotech Company BioNTech has shown the way with Cormirnaty®: stringent research and adherence to milestones ultimately lead to success. The main and founding investors Strüngmann are still on board as long-term investors with over 40% even after the price correction. The mRNA technology is now mutating into the basis for a whole new class of drugs, and BioNTech could thus become a new German pharmaceutical giant. The brothers from Tegernsee know what they are talking about. Their start-up capital came from the first major exit after they sold their generic drug manufacturer Hexal, founded in 1979, to Novartis for EUR 5.65 billion in 2005. Since then, they have continued to invest in biotechnology through their family office. The challenge is to find the next BioNTech.
Read
Commented by Carsten Mainitz on July 28th, 2022 | 13:35 CEST
BioNTech, Defence Therapeutics, Valneva - Will the fall bring a new boost?
Officials expect the Corona pandemic to intensify sharply in the fall. Already, the number of cases is rising, as is the number of hospitalizations. To be better equipped against the currently prevalent Omicron variant, BioNTech/Pfizer have specifically adapted the Comirnaty vaccine to it. Valneva's recently approved vaccine also provides good protection against Omicron through a broader immune response to its inactivated vaccine. Also involved in vaccine development is the Canadian company Defence Therapeutics. It is currently attracting attention with its cancer-fighting developments and could become a real gem.
Read
Commented by Fabian Lorenz on July 21st, 2022 | 11:34 CEST
Buy now? BioNTech, Nordex and MAS Gold
The mood on the world's stock markets has stabilized in recent days. Hopes are alive that inflation and the US dollar have seen their highs for now. Even a soft landing of the US economy is no longer ruled out. Therefore, for example, JPMorgan and Goldman Sachs advise buying shares because, from the perspective of the US banks, the chances of a V-shaped recovery of the stock markets are increasing. That could benefit stocks that have fallen by the wayside in recent months, including BioNTech. The Wiesbaden-based Company could be in for an exciting fall. A weaker US dollar would give a boost to the gold price. Gold explorer MAS Gold should be able to profit from this. Nordex has at least full coffers after two capital increases but continues to have problems. However, Jefferies advises buying.
Read
Commented by André Will-Laudien on July 18th, 2022 | 15:04 CEST
Fall is coming: BioNTech, Defence Therapeutics, CureVac, Valneva - Which biotech stock will surge again?
The summer of rising incidences is making its way, but the public has already shelved the pandemic measures and hospitals are filling up again. Even if no one wants to talk about it anymore, the fourth wave is coming! Worldwide, the race for suitable vaccines or treatment methods continues. Medicine is still relatively helpless as far as treating severe cases is concerned, and the subject of post-COVID is considered completely unexplored. We take another critical look at the landscape of biotech stocks.
Read
Commented by Fabian Lorenz on July 13th, 2022 | 14:27 CEST
MorphoSys facing a takeover? Exciting autumn ahead for BioNTech and XPhyto
Biotech investors could be in for an exciting autumn. After some sharp price corrections, positive things are happening again in the biotech sector. For one thing, the takeover carousel. It all started in June when Pfizer announced the acquisition of migraine specialist Biohaven for USD 11.6 billion, and GlaxoSmithKline plans to swallow Sierra Oncology for around USD 1.9 billion. Recent deals include the acquisitions of ViaCyte, La Jolla Pharmaceutical and Pliant Therapeutics. MorphoSys is also a possible takeover candidate. It could be a win-win for the German biotech company if the price is attractive. Xphyto could also see at least one investment, as a market-ready product has great potential.
Read